Ocular PBM Research Library

Update: FDA Authorizes Photobiomodulation for Dry AMD

January 2025: The FDA has authorized light therapy (photobiomodulation) as the first non-invasive treatment for dry age-related macular degeneration. This regulatory milestone validates the growing body of research demonstrating red and near-infrared light's therapeutic potential for retinal health.

Read FDA Update from American Academy of Ophthalmology →
Browse Research by Category

Safe and effective: precise energy, clinical photobiomodulation light spectrum and timed dose are fundamental to the WaveFront’s vision support and macular health.

Primary, peer-reviewed research is at the core of WaveFront development. Below is our Research Library–the published, primary scientific resources we use to guide the design and output of the WaveFront. Our research is comprehensively updated as published studies become available, incorporated into our research & development and ultimately, our products.

We are pleased to make these resources available directly to you here–each is linked to its publication site and is summarised (Abstract) for your convenience.

To inspect the WaveFront’s output for safety and efficiency, find our WaveFront Evidence Alignment paper that synthesises key WaveFront energy and spectrum output with scientific studies in our Research Library.

Clinicians: we have prepared an ocular condition vs WaveFront output paper for your reference here

 

Vision Support & Macular Health

May 21, 2026

THE definitive PBM mechanisms paper: CCO photon absorption → NO release → ATP boost → ROS signalling → transcription factor activation.
Vision Support & Macular Health

May 13, 2026

Red Light Therapy for Glaucoma: Science, Safety, and What the Research Shows outlines how photobiomodulation supports retinal ganglion cell health in glaucoma — neuroprotection mechanisms, peer-reviewed evidence, safety, and compatibility with prescribed care.
Vision Support & Macular Health

May 13, 2026

Red Light Therapy for Eyes at Home: A Guide to Safety and Vision Support examines the science behind ocular photobiomodulation, details necessary safety and device selection criteria, outlines evidence-based clinical benefits for various eye conditions, and provides practical protocols for consistent, effective home use.
Vision Support & Macular Health

May 13, 2026

Red light therapy for eye inflammation: For people managing chronic dry eye, blepharitis, age-related macular degeneration (AMD), glaucoma, or other inflammation-driven eye conditions, PBM has emerged as a non-invasive way to support the cellular environment of the eye alongside conventional care.

May 13, 2026

This guide evaluates the clinical efficacy of light therapy for recalcitrant cysts, details the biological mechanisms that restore glandular function, compares professional and home-based devices, and outlines essential safety protocols for managing long-term eyelid health.
wavefront in the lab

May 13, 2026

Low level light therapy for dry eyes has emerged as a way to support eyelid glands at the cellular level. This guide walks through how light therapy works for dry eye, what the peer-reviewed research shows, how at-home approaches compare to clinical light treatments, and what to look for when evaluating any device intended for use near the eyes.

October 11, 2025

Primary outcomes included change in tear breakup time, self-reported patient satisfaction, and adverse events. Physician-judged improvement in dry eye tear breakup time was found for 68 of 78 patients (87%) , and 93% of patients reported post-treatment satisfaction with degree of dry eye syndrome symptoms.
wavefront

October 11, 2025

Shergill et al. (2024) reviewed IPL and light-based approaches for ocular rosacea, noting improvements in gland function and inflammatory control—mechanisms also engaged by PBM at 670 nm and 810 nm.

September 13, 2025

Photobiomodulation (PBM), also known as low-level laser therapy, is an emerging therapeutic modality in ophthalmology for its potential to manage a variety of ocular conditions. PBM employs low-energy light within the red and near-infrared spectrum. This interaction is believed to enhance mitochondrial function, boost adenosine triphosphate (ATP) production, and reduce oxidative stress, leading to improved cellular repair and tissue regeneration.
Vision Support & Macular Health

September 13, 2025

Red LED light with a wavelength of 600–700 nm enhances the immune response and cell proliferation, and NIR LED light with a wavelength 800 nm exerts anti-inflammatory effects. Several studies reported that PBM effectively improved the tear breakup time and tear volume and reduced the inflammatory response.
Load more